Matthew Scholz

Matthew Scholz is the Founder and CEO of Immusoft, a biotech start-up developing a breakthrough technology that turns a person’s cells into miniature drug factories. Immusoft’s proprietary technology platform has the potential to transform the landscape of biomedicine and eliminate the need for conventional treatments for many diseases, including HIV and cardiovascular disease. To date, Immusoft has received funding from Peter Thiel’s Breakout Labs, the National Institutes of Health and private investors. The initial concept for Immusoft’s core technology was based on using high-speed cryptographic hardware to develop novel proteins to fight pathogens. The idea evolved when Matthew concluded that a system developed by Nobel Laureate David Baltimore at Caltech could be modified to program resting B cells to secrete therapeutic proteins. With an exclusive license to Baltimore’s system, Matthew, a computer scientist by training, created and patented a way to improve its efficiency and make it clinically viable. This modified system became central to Immusoft’s technology platform. A sought-after speaker on innovation and entrepreneurship, Matthew can frequently be found discussing those topics at conferences and at his alma mater’s business school, the University of Washington’s Foster School of Business. He is also a Thiel Fellowship mentor.